John Oyler (#2321)
- $ 2 B
- Biotech
- United States
- M
- 58 Years
Rest in Peace Ask Jeeves, every search comes to an end
County commissioners call on lawmakers to up funding for 911 dispatch systems
Spirit Airlines Is Going Out Of Business; Effective IMMEDIATELY
Pokémon Scalpers Selling Limited-Edition Pop-Tarts For Ridiculous Prices
Bennett says Netanyahu gov't 'boycotting' West Bank settlements amid Carrefour subsidy deal
Golf gear on sale now: Up to 65% off adidas, 45% off Puma, 15% off Mizuno, more
Families across the US can't find childcare — this map shows where it's worst
Median sales surge 61% in a Queens neighborhood that’s now the fifth priciest in NYC
Greg Brockman says his stake in OpenAI is worth nearly $30 billion
TeraWulf Announces Participation in Upcoming Investor and Industry Conferences
About Me
John Oyler is the CEO, cofounder and chairman of global oncology company BeOne Medicines. He owns nearly 5% of the publicly traded company. BeOne Medicines, which was formerly called BeiGene, was founded in 2010 as a research and development firm. It went public on the Nasdaq in 2016 and listed in Hong Kong two years later. Before he cofounded BeOne, Oyler helped start and then sell two companies in the U.S. and China. He sold Telephia, a consumer telecom research firm he founded in 1997, to The Nielsen Co. for $449 million in 2007. Oyler's next success came with drug discovery outsourcing company BioDuro, which he founded in 2005 and sold to PPD Inc. for $77 million in 2010.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped John Oyler’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking John Oyler’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $1.8B
(May 4, 2026)
© Iconic Billionaires